<SEC-DOCUMENT>0001193125-17-338081.txt : 20171109
<SEC-HEADER>0001193125-17-338081.hdr.sgml : 20171109
<ACCEPTANCE-DATETIME>20171109080803
ACCESSION NUMBER:		0001193125-17-338081
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171109
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171109
DATE AS OF CHANGE:		20171109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wave Life Sciences Ltd.
		CENTRAL INDEX KEY:			0001631574
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			U0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37627
		FILM NUMBER:		171188336

	BUSINESS ADDRESS:	
		STREET 1:		8 CROSS STREET
		STREET 2:		#10-00
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			048424
		BUSINESS PHONE:		617-206-4830

	MAIL ADDRESS:	
		STREET 1:		8 CROSS STREET
		STREET 2:		#10-00
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			048424

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WAVE Life Sciences Ltd.
		DATE OF NAME CHANGE:	20170516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences Ltd.
		DATE OF NAME CHANGE:	20151106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences LTD.
		DATE OF NAME CHANGE:	20151106
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d492837d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">FORM&nbsp;8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of report (Date of earliest event reported): November&nbsp;9, 2017 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Singapore</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-37627</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>8 Cross Street <FONT STYLE="white-space:nowrap">#10-00,</FONT> PWC Building</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Singapore 048424</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>048424</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +65 6236 3388 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (<U>see</U> General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2017, Wave Life
Sciences Ltd. (the &#147;Company&#148;) announced its financial results for the quarter ended September&nbsp;30, 2017.&nbsp;The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current
Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and is incorporated by reference herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this Current
Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as
amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following exhibit relating to Item 2.02 of this Current Report on Form <FONT STYLE="white-space:nowrap">8-K&nbsp;shall</FONT> be deemed to
be furnished&nbsp;and not filed: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d492837dex991.htm">Press release issued on November&nbsp;9, 2017 </A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>WAVE LIFE SCIENCES LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;9, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Keith C. Regnante</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Keith C. Regnante</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d492837dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g492837dsp1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Wave Life Sciences Reports Third Quarter 2017 Financial Results and Provides Business Update </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CAMBRIDGE, Mass., November</B><B></B><B>&nbsp;9, 2017</B> &#150; Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering
transformational therapies for patients with serious, genetically-defined diseases, today announced financial results for the third quarter ended September&nbsp;30, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Through the growth of talent and capabilities in our organization and excellent execution throughout the quarter, we achieved our ambitious clinical and
research goals. Importantly, we initiated our third clinical program of 2017 with a Phase 1 study investigating our DMD Exon 51 program, <FONT STYLE="white-space:nowrap">WVE-210201,&#148;</FONT> said Paul Bolno, MD, MBA, President and Chief
Executive Officer of Wave Life Sciences. &#147;Our first peer reviewed publication was featured in <I>Nature Biotechnology</I>, highlighting the founding principles of Wave&#146;s stereopure chemistry platform and approach. With the initiation of
our first three clinical programs this year and another three programs recently announced, we are on track to meet our objective of six development programs underway by the end of 2018.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Update </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>DMD Exon 51 <FONT STYLE="white-space:nowrap">(WVE-210201)</FONT> program initiates clinical trial </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On November&nbsp;6, Wave announced the initiation of clinical development for <FONT STYLE="white-space:nowrap">WVE-210201,</FONT> Wave&#146;s
lead program for Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping. We expect that data from the Phase 1 trial for <FONT STYLE="white-space:nowrap">WVE-210201</FONT> will be available in Q3 2018 and will facilitate the rapid
transition to an open-label extension study and efficacy study. Both studies following the Phase 1 are designed to include an interim efficacy readout of dystrophin expression from muscle biopsies in 2H 2019. The company is exploring both
intravenous and subcutaneous administration. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Huntington&#146;s disease allele selective programs <FONT STYLE="white-space:nowrap">(WVE-120101,</FONT> <FONT STYLE="white-space:nowrap">WVE-120102)</FONT> clinical trials on track </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The company&#146;s <FONT STYLE="white-space:nowrap">PRECISION-HD</FONT> program, which includes two Phase 1b/2a global clinical trials
evaluating <FONT STYLE="white-space:nowrap">WVE-120101</FONT> and <FONT STYLE="white-space:nowrap">WVE-120102</FONT> for patients with Huntington&#146;s disease (HD), continues to enroll and it is on track to report topline data in 1H 2019. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>First peer-reviewed publication in Nature Biotechnology </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In August, Wave announced its
first peer-reviewed publication in the September issue of <I>Nature Biotechnology</I>, representing a significant scientific advancement for the oligonucleotide field. The paper, entitled &#147;Control of phosphorothioate stereochemistry
substantially increases the efficacy of antisense oligonucleotides,&#148; describes a breakthrough method to produce antisense oligonucleotide (ASO) therapeutics with high stereochemical purity as well as rational drug design to control
pharmacologic properties in nucleic acid therapeutics drug development more broadly. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The paper outlines early foundational principles
discovered by Wave to engage RNase H1 that can be applied to any ASO sequence, and demonstrated that stereochemistry plays a central role in oligonucleotide drug design, with the potential to improve stability, duration of activity and specificity.
The company&#146;s highly efficient manufacturing process may allow for these key findings to translate into breakthrough treatments by applying nucleic acid therapeutics. Wave is continuing to leverage these initial findings to further build its
knowledge base and expand its platform capabilities beyond antisense, including ongoing work in exon skipping, single stranded RNAi and other modalities. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Pfizer collaboration progress </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The collaboration with Pfizer continues to make progress
on developing genetically targeted therapies for the treatment of metabolic diseases, including nonalcoholic steatohepatitis (NASH). As an update, our APOC3-GalNAc ASO findings demonstrated a potency equivalent to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> GalNAc conjugated double-strand RNAi with a median effective dose of 0.3mg/kg <I>in vivo</I>. In addition to a
<FONT STYLE="white-space:nowrap">7-</FONT> to <FONT STYLE="white-space:nowrap">10-fold</FONT> improvement in potency, an increase was seen in durability over GalNAc conjugated stereorandom APOC3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The collaboration has accelerated the application of Wave&#146;s stereochemistry platform across antisense and RNAi modalities with the
incorporation of GalNAc and Pfizer&#146;s hepatic targeting technology to address disease of the liver. Wave continues to advance its research efforts in this area. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In addition, Wave amended its collaboration agreement with Pfizer to extend the target nomination period from November&nbsp;5, 2017 to
May&nbsp;5, 2018, which provides Pfizer with an additional six months to nominate the two remaining hepatic targets under the agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Third Quarter
2017 Financial Results and Financial Guidance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave reported a net loss of $26.1&nbsp;million for the third quarter of 2017, as compared to a net loss
of $17.5&nbsp;million for the third quarter of 2016. The increase in net loss for the third quarter was mainly due to increases in research and development supplies and services expenses and increases in compensation-related expenses as Wave
continues to grow its employee headcount to support its corporate goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses were $20.1&nbsp;million for the third quarter
of 2017 as compared to $13.7&nbsp;million for the third quarter of 2016. The increase for the third quarter was driven by increases in research, discovery, development, preclinical and clinical supplies and services expenses, as well as increases in
compensation-related expenses, related to the continued growth in employee headcount, and increases in facility-related expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative expenses were $7.6&nbsp;million for third quarter of 2017, as compared to $3.9&nbsp;million for the third quarter of 2016. This increase for the third quarter was due to increases in compensation-related expenses, related to the
continued growth in Wave&#146;s employee headcount, as well as increases in facility-related expenses and other general operating expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;30, 2017, Wave had cash and cash equivalents totaling $168.5&nbsp;million as compared to $150.3&nbsp;million as of December&nbsp;31, 2016. The increase in cash and cash equivalents was due to the $93.5&nbsp;million in net proceeds
from the April 2017 <FONT STYLE="white-space:nowrap">follow-on</FONT> offering which was partially offset by Wave&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> net loss of $71.8&nbsp;million.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave expects that the capital resources available as of September&nbsp;30, 2017, together with anticipated milestone payments under its existing
collaboration with Pfizer, will be sufficient to fund its operating expenses and capital expenditure requirements into <FONT STYLE="white-space:nowrap">mid-2019.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Wave Life Sciences </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave Life Sciences is a
biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases. Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver
superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements concerning our goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following: the anticipated
commencement, data readouts and duration of our clinical trials; the protocol, design and endpoints of our clinical trials; the future performance and results of our programs in clinical trials; the progress and potential benefits of our
collaborations with partners; our identification of future candidates and their therapeutic potential; the anticipated therapeutic benefits of our potential therapies compared to others; our advancing of therapies across multiple modalities and the
anticipated benefits of that strategy; the anticipated benefits of our manufacturing process and our internal manufacturing facility; our future growth; the potential benefits of our stereopure compounds compared with stereorandom compounds, our
drug discovery platform and nucleic acid </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapeutics generally; and the anticipated duration of our cash runway. Actual results may differ materially from those indicated by these forward-looking statements as a result of various
important factors, including the following: the ability of our preclinical programs to produce data sufficient to support our clinical trial applications and the timing thereof; our ability to continue to build and maintain the company
infrastructure and personnel needed to achieve our goals; the clinical results of our programs, which may not support further development of product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of
clinical trials; our effectiveness in managing future clinical trials and regulatory processes; the success of our platform in identifying viable candidates; the continued development and acceptance of nucleic acid therapeutics as a class of drugs;
our ability to demonstrate the therapeutic benefits of our candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our ability to obtain, maintain and protect intellectual property; our
ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; our ability to finance our drug discovery efforts and to raise additional capital when needed; and competition from others
developing therapies for similar uses, as well as the information under the caption &#147;Risk Factors&#148; contained in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the Securities and Exchange
Commission (SEC) and in other filings we make with the SEC from time to time. We undertake no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jillian Connell </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-949-2981</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jconnell@wavelifesci.com </U></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jose Juves </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">617-949-4708</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jjuves@wavelifesci.com </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patient Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wendy Erler </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-949-2898</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>werler@wavelifesci.com </U></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except share amounts) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">168,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">202,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">164,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Series A preferred shares and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of capital lease obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of lease incentive obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital lease obligation, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease incentive obligation, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at
September&nbsp;30, 2017 and December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, no par value; 27,767,905 and 23,502,169 shares issued and outstanding at
September&nbsp;30, 2017 and December&nbsp;31, 2016, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">309,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(162,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90,477</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">165,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, Series A preferred shares and shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">202,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">164,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except share and per share amounts) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,992</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,919</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,520</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit (provision)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(384</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,535</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(71,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to ordinary shareholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average ordinary shares used in computing net loss per share attributable to ordinary
shareholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,758,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,445,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,078,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,571,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g492837dsp1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g492837dsp1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MJE6$9M75_=E&TENKZG8^$_B[^R'^T-I,/@7Q?\,?#?P;\9-)K4WA.>18]/\
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MDHN+36MM=-/NWT/:CB</*%.I'$4I4JO\.2G'EEI?W6G:5EKH]B7[9:^<MO\
M:;?SV59%@\Z/SFC;.R18MVXHVTX8 @[3@TN2:7-R/E6C=G9/U*5:C[14O:P]
MK))QASQYFNC4;W::78H/?ZFNHSVD>B326,>GFY@U7[=8I!<WH8@:8+5I?M$,
MA7!\]H_*Z@G/6U"E[.,O;I3YE%PY9-QCUGS)<ME_+?F\C"5?$QQ%2E' RE0A
M2<X5E4I)3J]*/(Y<\7_T\DN3S/(]6O?V@]6OI+?P[H7P\\(Z1/!#Y.I>(=4U
M+Q!K5A(!BX\W3=(CBLIY2V?*5;AHU4*7D)8JGM4(<-4:2EB:^,QE>+?N4(0I
M4I+HU*I><4MI/ENWLDM_B<?7\2\9BG2RG 9-DV!E&/+7QM:MBL32:?[S]UAK
M492E;W%=P2:YI-W2GMOA5KVL"-OB1\2O$WBV-=KR:'HBP^!O#3M@YBN+;P^R
M7^H6XW%0ESJ+(P'SHW:9YOAJ.F5Y51P;5[5*K>)K>JE5O3A+K[M--/9ET.#L
MSQBA+BKBS'9TEJ\+AHPRO!/O&I3PC5:K!:I>TK6DK\T6>->*OVC-+\ 7\O@/
MX3?#3_A(;73+A-+L;S1PUGX;N-5;:EQ9Z7!I>GROJT\-VXAF>)P7E27YCM+G
MZ' <)U<RHQS'.\WC@G-.<HU7SUX0WC*IS2C[.+CK&Z=E:RNTC\\S[Q;P?#.,
M_P!6N"N$I9Q'#U%AZ=3#7IX.I7T4X4/8TIO$3ISO&I*,DY2C)\S2YG\?_&[Q
MI\9]:U9-)^*(O-!BU!+?6=.\&QF&#3+>!6FM;2XBL(;FXF>0.EPF^ZD:1G#G
M P /T#AK+>&L/0=?*''%SHMTYXF>L[I*4KS:C'9IM0BDHVUZG\_>)7$?B3F&
M.6 XNIU\LI8Q4\10RRG[E%0O*G3DJ<95)-N49)^TDYN5_)+B?AU\/I_B%KZ^
M'H_$&@>&[QR([./Q'=3V,NJW@.6TO2T6TE$NH^4K-MDV!24!W,X4^GG&<PRC
M"?6H8>IC81NFZ%I1IQ:LJD_>7+"^EU=O7HF?,\'<&5>*\V_LJ6983)ZRNH+&
MRG1GB*B:YJ&'2IR3JI:J,G'HKW:/U!\+_"H:98Z)X.T*%=!^%^FK;:W>W,-]
M<Q>-/&?B)9@9K;79!8P_V9I1D@BEFEL[@R74<<-LGDV>])?Q'&9S+$U:^/Q3
M=?-JK=.*E&/U?#T>6R=.+;YJEFU%2C:#O-\T]5_;F2\%PRS#9?D.6067<*8.
M,,35G"I)9CF6-YES0Q4U"+HT5*$95)4IWK14:,>2C=/Z(KYP_33Y0_:9_:M\
M+_LX:9IKWFD7/B;Q#JVH06MGX;BO/[#N9K)HQ/=ZM:7FH6$D&HV=M$!%*]H+
MGR+BYM8YU02DK]1PSPKB^)<14I4:L<-1I0<I591<X)K10DH.\92U:YK72=GH
M<F+Q<,'3YG'F=TE%;OS^1^0WQ*_;P^-'Q1\):[X"UFQ\"KX6UT3VE\I\,R2:
MI?:29"]G!>R3:M+:PZA$Z6MP;FS@@VW%NK1!$ 6OV'*?#_*,KQ>&QU*MB7B\
M/RRC:K%4U.UI.+4(RY7=I1DW[KL[GR>/SC$U:=2@X4XTI:-<MVXWT^UH]%M:
MS/D_5KW2[^XMKC2]$CT!?LD$=[96^H7>H64U]$"LU]8K?!I]/@G 1S:/<70C
M??Y<@C98X_L\/2KTH.->N\5:<G&;IQA-0^S&?*^6;CTJ*,6^JOJ?$XZ4)./)
M#V:2NU=O7Y[>FOJ4X99;:>"YMI9;:YMIHKBUN;>5X+FVN('62&>WGB99()XY
M%5ED1E964$$$5U\D:D'"HE*$DTU)735K--/=-:-/1GR6+DZ4N:'NRB[IK22=
M]&GNK=.Q];_"?]L[XZ_#86>D3>*AXS\*+=1"\T;QU:R^)I([%Y0+N.SU26[A
MU( 0O(R0/>O'N50%4$U\9F_ 60YE&=:CA/J&*Y9<DL-)4ESJ/NN5.SIVNE=J
M*EOJ>CEO&^=Y:XTJF)^NX6,ES1Q$?:^[>[M.ZFK+9*=EV;/V;^&_[0GPN^,*
M6FD^%_B)H$VK26_VG[%IUY=>&?$HN8YOW-I#X8\26GFW"?9V!D\J:\C5XROS
M(5<_A>9<.YQDSE4QN75:=).W-**J4K=_:TFTF^EU!M:VOM^S9;Q'E&<<M/!Y
MC2E5:NHJ3I5;WLDJ=5)R[M1<TFK.ZWMZMI?[/_Q1V:%XTT[P?XK\0VFH/X;N
MH/%.E:;;^,H]6LF^SR17 AM;:[M7E?!2:V\JVF\Y?(9ED4'.AB,]RS]]@Z^(
MPE&4543HU)^PY):JRYI1:7:5Y+JB<1AN',VY</CJ&&Q>)A.5)JO3@L0JD?=E
M=Q49Q;_FBTG]E]#R'7OV'/@1XP\.7=EHWAW_ (0'6UU"ZELM:\.^(+WQ(;?#
MI (IX-6G>*ZT]D@)-FZQ-"\DGERJQ)/O87C_ (CP6(A4KXI8^CRQ4J-:E&$6
ME=IKDBG&6ND];K=,^<QGAIPSC\)4HX;#2RNLYR<*U&M.K9JUU)3DTXNWPWC)
M.]I+KYRW[%_QM\.Z6V@>!_VC]7@\.V$$,^C:+=KK^DP0:A:WT=];Q1)I^L7,
M6E0K/$LHGM8RP8%#"8W;/J_Z\Y#BJSQ./X6HRQ-2;56<?9S;@X<DF^:$7*36
MEG96UO=(^=GX:\3X2A]6ROC.O#"TE&5*E/VU-1G"7-%14:DE36E^9:WNG&SN
M?1>B77[4&AMHFC:MH7@CQ-IOARQT]-:\26^NM_PD'Q :,W%O=/80W<&GVGAC
M5"JV5S)%=07,#B298KM749^6KQX6KJM5I5\3A:F(E-TZ+I)T<)9IQYI*4YUH
M;Q3ARRCHW'37Z_#5..\)]4PU;!X''T<'&'MZ_MVJ^-LI*7LU)4X8>M;E;512
M@^D]7R^U>"O$%UXHT]]8N]'\3>&;E99+"X\.^)=*32KJPG@(F+((YKB/4D*S
MK&+^TNI;6<0YC565A7B8S#1PE7V,*U+$1TDJM&;G&2>F[47%Z:P<5*.SN?49
M9C)XVB\14P^)P4XOV<L/B*2ISIR7O=')3T=E4A-PFDFDG<VC<:%=ZB8I?L$V
MJZ,RE3<0Q_:[!KRVD(>UFG0,@EM1*"T#$%5D4GY6 P7M84U9R5*IT3=I6?VH
MKJG:U_)G2WA)U_>A3>)PVB<H+FASQ;M&4DG:4;WY7:UTWHSPO0-<^ ?C:XU'
MX;Z3X<T^XTVT>\\7):7/A.ZTOP_?WD=QMU74= :\M8#>W4,LH$\EG%M*W'RL
MZ.V?>Q&'S_ PHYG6Q$HU*BC04HXB%2K&+C>$:BC*3BG'X>=IZ6T:/B<'C>",
MWJ8GAS#X"$J&&<L;[.>#JT<+4G"7[VIAI3A!5)TY?Q/9JVNG,FSC[WXG_L[6
MNIZ9K^@^&K7Q-XB\+QW<6BWVD6%A%=:23=WRC3OM^J7]K_9\.;JZN+>WFQ''
M#= P(F0B]L<KX@]G/#8K%K!8?%\DJD:LW:HN6+4^6$9<[5DI-:\R?,SPJ_$_
M 5.O3S#+\IGFV/R=RA1JX>@E*A-2G%475K5*?LE*\G3C/W>67NI+126'[5]E
MJLDEIIOP\U]=1CEDACLM2O[>WEG:)-SS0#3;34'GM!@@30QR D'&1S6D^#94
M%&I/-<.Z/+?VE-.45VC+FE3Y9?W96L<5'QCI8J<\/1X5Q]+%QDX*C7FJ<W;5
M3BJ5*O*5)O3GBFKWZ:G<Z;XU^+/BV)CHWAK3?#"D*5DU+2/$6I.JL(VREQK:
M>&K>1@K,084NU^7!YQGS:N"R?!2BJM>IBG%V<83I4U;NN3V\K>MCZ#!Y]QEG
M=*?U/+*&47BG&=>ABJUGNX\U;ZG2<DGI926VVQPNJ^#O%7B6^M/#/Q"^.&NR
M76KW\M_IGASX=Z7#I]^--M[.2SO(M4U'2;=TMM-8R3HS7<?E>:(]L[."M>C0
MS#!8.'UK+>'Z,50@H5*V,J2JT_:.5XRA3GRWFM'[KNE]E*Q\[CN',\S:O'*^
M)O$#&2>-K2JX?!9-AXX:JJ,*3A4A7KT%*,:4ESIJK>#DU:;DF>2Z;K5SY/\
MPCWP3\&W'PRTOPC<7.B>*_B]\2(-,?4=!TT7+PW,-K=ZW.WV:\61II&L;>1F
M D\M;>'*N/<JX>GS?7.(,?'-J^.BJN'RW!.?+4GR^ZYJFE[FR4FK:7YI6L?#
MX7,L0H?V1X?\/U.$<#DE6IA<QXESR%%5,-055PFZ4\1*WM?CDZ4&Y6ERJ%/F
MYG]%W/Q&^$_AOP[#\3[WQ1_PF&GJVC^"VUFVTW3=0N7U*QC DG'EV$-V)G;S
M+N?,[QH)=T,8\Q0_R]+*,[Q6,ED]'"/!5DJF)5*4YP2@]4G[SAHK0CHF[6D]
M-/U.OQ9P1EF4T^+L5FT,[PJEA\M^LPH4JTY8BE&TI0C[.-52D[U:MI.,4WR1
MU2?DGC;4O#OQDUG2AXOU"V^&_P ,?#$S>)VCOKBRTSQCXAFE0PVFK:L@E67P
M9I-U%YD=G'-NU&[,CR+#&$22#W,MAC,AHUE@*4LTS;&16'3A&=3#4=G*%.ZY
M<15@[<[7[JG:SE+6_P +Q#7R7C['8)YYB:/"W"64R^O\M6='#YEC6TU3Q%>*
MDIX##U5>-",^;$UVW)4X^[*'T3X ^+/PG\3S6WA+P+XETZZN-+LWM;#1HHK^
MUE&G:1'';!K);Z",W-I' L95T9]R8;D9-?+YGDF=8",L9F.#J4H5)<TJDN5K
MGG=V?*W:3=]+*SO8_5.&N.."\\JPR?AS-Z.)JX*FX4\-%55+V.'2@G!U(KGA
M%6L[RDUJ^K/7J\4^W/*?BU\(_#/Q?T*WT'Q-::3<6MO<-(K:EX:T#Q!(L,JJ
MEU#9R:U8S2Z3-(J)BZT^:UG4QJ=Y Q7H99FF*RG$.OA:M2G)6NJ=6I3NU\/-
MR-*<5_+)2B[M6,JM&%:/+.*:Z-I-KT['Y%_'K_@G%XK\!:9>^*_@_J^H_$/2
M;20RW?@^]LX(_&%E8+$&DN-+GLRD'B,QS+)FTCMK6X$13RQ<R*P/[#P]XDX;
M&U*>#SNC# SEMB(-^RG/I&HG=TK_ ,RE*-_BY5J?*YED52$75PG[Q+7D?Q?]
MN])>FC]3\W2DD,KP2QR03V\KP7%O-&\%Q;SQL5D@G@E59()D8$-&ZJRD$$ B
MOU&$HSA&I!\].>L91>EO)KH? 8V\7RR5I1OIU7RZ$G3'L1_.MH=#Y'':7MT+
M<7&<?A[56MM^6Q\_4T3TT70VPT*S1RV8N(!"+=XVDF5KF*ZCB3SIHIX(HO+'
MVE9'BV@.B%%+,REVQ47R.,U&<=5RV7+;;5.]W;2W74XZLN22E2O"<;6=[6ZW
M3Z.ZO^)Z;J/CKXI:SI>EVNK^)_%>J:7X6FGO-+NVO+BZ.BRWTOV:6X77K;=<
MPB::,1YFNRKNGRY8#'D4,JR3#5JOL<+AZ57&KDG#EC!5(PULJ;?+[M[RY8WM
MU*QF;9Y7HTH5<76K4L"^:%3G<O9N=E?VJU;?*K7>C6EM3I-"^.OQAT2%[33/
MB5XK@MIC$9[>35'NUN/LZ@1+,]V))9%C"C:OF?+U7!))Y\1POD&(:G4RG#\T
M4TN6/([/=Q4'%)KI?8RH\7<2X-.%+-\2E+ENY3E-NS]U/GYKJZZ'U3X)_;[^
M*NA0_8_$^CZ)XLMVGBF>\BN+W0]801F$&*"5C?V,<+11%3$E@BY=F&&)8_'X
M_P ,LIK/FP.*K8.:T4)QC6IZW:>G+-6O_-*WX'UV7^,>=X1>RQ^$I8^*E'WX
MRE2J)1TDF[SAK:[7(K^3=SZ*L?\ @H;X5OD99_!>JZ%-Y"E&N9DUFW%RI!9#
M]@$,C6[9VA_+1E +;2<*?F*OACF-*WLL92Q"N]OW7II/FL^N]CZNEXW9343]
MIE]7"-);OVOO+7=<EHO9=5O:RU]2T?\ ;;^$M_.ZW<EU90%8!;.KVYE>5G=)
M_.BU&2Q,$*81E;EF5_N@@@>/6X"SRC%_N5+EO=O33965/VDFWT5GIK<]S"^+
M_"U6:C4JSIJ7*HJ,>9\SWYIU/9027>_?0]FT7X\?##Q#,(-/UZ&5@$=7<0-
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MYWY?=B^6--<W-*[5U%:WD^4_JGAGP)P']EY-B^(J6,S;,\VE2GB*=+%0H87
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M&RM91BDDK=>O4O5F= 4 % !0 4 % !0!&\L<6-[HF>F]E7..N-Q&<>U $@H
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MC;Y!^@B7=J[2)'<0,T#;9E6:)FA88!655<F-@2!AL=1ZT?H'Z%B@ H * "@
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M#M#OL?<W[*OQ!_:#^(GA'Q)J?[1'PQLOA;XEL/$QL-!TFQMKBVCU'0!I6GW
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MZ;8>._#%W?7]]=2+#;6=G:6^IM+<W4LK*B11JS,S *"31L*UOD>L_P!/TQ0
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MM=?1"&UN.PCOOM92WE^TC;IUML!V[?FZ[N#;Y#4G'8^9?^'3W[)G_/K\1O\
MPMY/_E;1M\A\S.D\&?\ !,G]F+P%XO\ "WC?0;;QZNN>#_$&D^)=&:\\827-
MHNIZ+>17UD;FV.GJ)X!/"FZ/<NX9&1FC;Y"<G:Q^A/2@04 % !0 4 % !0 4
M -?A&QQM4D8[8!Q1^@?H<5\--2O]9^'G@?5]4N7N]2U3PGH%_?W<BQI)<WEU
MIEM/<3NL2(BL\KNQ"*H&> !Q1^@;?(\E?Q)X@OO _P );J>Z\67]WXAUV_M]
M9'A*33[77M1AMO#_ (NO85$EQ+:PQ6L=SI]G)((Y(V(@0?,"RL;>0;>5C<\;
MW>K:'X-\&IIDWCOSM9\:^'K*^M#J&F'QI)8:E)=S76EB^N[M;2WD4Q)NVW:[
M8H75)<D;@/T/2_!]K-;:0'G7Q3#+<3RS/:^+[^RU#5[7:1"L9FTZ[NK=8&6(
M2HL<\G^M);:Q*J;?(-OD>?\ CV+Q-_;[W0D\</X4M= @-J/AS>:8NL:1KXNK
M][[4-:T:Z876O6TEC_9GV.WMDOD#VEXLME(9XVHV#83^T;[QCX@T#PQ:>*]3
MM- _X5[I/C2XU[05AT?4/&4FJWDEA;-;7+0-+I&GP169O;F&S6&;?K6GQF:.
M)'CN38-B7Q,VO>#/!?B?[-XQN]8GL=2\/OI%U?QV,NO:/8:AJVC6L^G:E=Q1
MA-21]]Z8+F>VCG\FX\N1YWA$[@&7K]YK5]\4-<T)%^(=SI-AX4\$W-LG@S5-
M#TRPTR[UC5O&=OJ%WJ9U'4[.XGEDATRQ(,*W(6.S;:H=L2 ;>1I^,M;\5>'_
M !EX9_L*:]U31])\'^(M8\1^&8X(+J]\0V%GJ_A6PEO+*9H_M#>(-.M;NZNK
M:")U6]+3VKKYEQ!+;FP;&(GCO6+W0/$-YH^M13)K'Q6TCPAX<\0K#:WEIHFA
M>(HO#$=MJ-M$83#>/&NI7'V5;H.C7=Y;I.&0-&3;R#;R/1-*\+WWAS5M/FA\
M;Z[J&GW:7%KJ.C>*;JWU9]2NEMY+BWO-(O&C@GTR^B,,SRV\&^UD@\S%M$T2
MRH;>0;>1Q'P_EU?6=3EO]2'Q'_<^(?&(74;K5]$7P9<P:;XEUC3;*TM]-M=3
M:]%L+.*%(TDL8N;;=(P/S.;#V[:%.:X\0:1XHGU'Q1K'C/3+6?QI%::+KFF7
M&DZK\.GT&]U*WL=)\/ZMHL.+K1[N?S5TR>^NK7?'J$PGCOQ"R0H"/H$?E[>E
M !0 4 % !0 4 % !0 $<8[=,?_6HV\K <7X:\ >'/"!MAH1\106]G9_V?9Z?
M>^-?&FM:1:6:B,1P6NC:WX@N[&W6)(D2(QVZF) 4B*(2";>0?H:EEX6T#3K?
M0K2RTY(+?PS-/<:'$)KEQ837-I?6,[HTDS-*6M-2O8\2F0 3D@ JI4V^0"^(
M_#&C>*K*"PUJ&[D@M+^TU2TDT_5M7T2^M-0L69K6ZM=3T.^M+RVE0NX_=SJ&
M5V5@RL03;Y!M\B;1-!L?#UM+:V$^LSQ2SM<,^M^(_$/B:Y$C)'&5BO?$>J7U
MQ#!MC4B".58@Q9@@9V+ &1KG@3PWXAOCJ5_!JL%^]BFFW%WHGB7Q-X9GOM/B
MDFEAL]2?PWJ]B=3MX9+FZ,27?G"+[7/Y>WSY-YL&Q)J/@?PQJ5IH]G+ITMG'
MX>@%IH4^B:EJOAS4-'LQ!#:O8Z=JOA^^LKVTL9+>WMXY+:.X6*5;>(2(WEKM
M-OD&WR([;P#X3M-(O]#CTII;#5;R'4-5:\U#5-0U+5;ZVEM9K>\U36K^]FU'
M4KF-K*T59+FZE81VT<0/EH$!MY6#;R(]7\ >'-:U>;7;K_A(;35;G3[+2[JZ
MT'QGXR\+_:K+3IK^XL(KJ#PUK]A#<M!+J=^4EDC:11<NH?;@ _0/+L;\>BZ;
M#?6>IB!VU#3]*FT6UO)[J[N+A--N)K*XN()9+B=S<R23Z=9R-/-YDS-#DR?.
M^XV^0?H8MIX!\&V.CZ[X?M?#VGQ:)XEU/5-8UO2S&\EE?:GK,RW&I79@E=E@
MDFN$6;$ C5)%$D81_FH_0/T&:/X!\,Z'J46KVL&JWFIVUO+:65]X@\3>)_%5
MQIUO<;/M,6ER>)]8OSI2SB.-9?LGDF58T60LJ* !^ S3_A_X<TG4?[3T]_$U
MK*-0O=3^Q+XY\;MH8O-1N+F[O#_PC<GB%M)^SR75W<2_9OL7D*\FY8U*KM-@
MV&/\./",FIOJC6-_YDFK1Z]+IR^(?$B>'9M:BN$O$U2;PHFK#19KT7\4=X97
;L&8W4:7))N%$@-O(-CN.GX?TH * "@ H __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
